Aaron Ondrey - 08 Sep 2023 Form 3 Insider Report for Mirati Therapeutics, Inc.

Role: Interim CFO
Signature: /s/ John Moriarty, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 08 Sep 2023
Net transactions value: $0
Form type: 3
Filing time: 12 Sep 2023, 17:27:50 UTC
Next filing: 03 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	MRTX	Common Stock						14,028	08 Sep 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	MRTX	Employee Stock Option (Right to Buy)							08 Sep 2023	Common Stock	11,933	$65.79	Direct	F2
holding	MRTX	Employee Stock Option (Right to Buy)							08 Sep 2023	Common Stock	11,844	$45.66	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents Restricted Stock Unit grants with vesting periods of 4 years that vest 25% annually from grant date, which were August 1, 2022 and January 20, 2023.
F2	25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, which was August 1, 2022 and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.
F3	25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, which was January 20, 2023 and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.